



## **NEWS RELEASE**

### **Ocumetics Announces Transition of Chief Medical Officer Consulting Role**

#### **For Immediate Release**

**Calgary, Alberta – January 9, 2026** - Ocumetics Technology Corp. ("Ocumetics" or the "Company") (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO), a leader in next generation ophthalmic technology, today announced that it intends to form a Scientific Advisory Committee (SAC) to fill the role now being performed by a single Chief Medical Officer. In the result, the consulting agreement with the Corporation's current Chief Medical Officer, Dr. Doyle Stulting, will terminate following a ninety-day transition period.

As Ocumetics advances toward completion of its First-in-Human (FIH) study and prepares for a pivotal FDA clinical trial anticipated in 2027, the Company is evolving its medical and clinical leadership structure to align with its next exciting phase of growth and execution. The transition is from a single CMO structure to a broader multi-member Scientific Advisory Committee (SAC) structure. This committee will provide deeper and more diverse medical, clinical, and regulatory oversight as the Company advances toward late-stage clinical development.

It is intended that the SAC will be composed of internationally recognized experts in ophthalmology, medical research, and lens science, allowing the Company to leverage broader expertise across multiple disciplines critical to a successful pivotal trial and commercialization pathway.

The Company will announce members of the Scientific Advisory Committee in the coming months. Ocumetics remains focused on advancing its accommodating intraocular lens technology and executing its clinical and regulatory strategy to deliver excellent innovative solutions for patients worldwide.

Dr. Stulting has played an important role in Ocumetics' development, contributing decades of clinical expertise, research insight, and leadership to the Company's scientific and clinical programs.

"Dr. Stulting's resume and career speak for themselves," said Dean Burns, President and CEO of Ocumetics. "His contributions to ophthalmology and to Ocumetics have been meaningful, and we sincerely appreciate the experience, perspective, and commitment he brought to the

organization. We thank Dr. Stulting for his service and wish him continued success in his future endeavors.”

## **About Ocumetics**

Ocumetics Technology Corp. (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO) is a Canadian research and product development company that is dedicated to developing advanced vision correction solutions that enhance the quality of life for patients. Through innovative research and development, Ocumetics aims to transform the field of ophthalmology with state-of-the-art intraocular lenses and other vision-enhancing technologies.

Ocumetics is in the first-in-human early feasibility study phase of a game-changing technology for the ophthalmic industry. Ocumetics has developed an intraocular lens that fits within the natural lens compartment of the eye, potentially to eliminate the need for corrective lenses. It is designed to allow the eye’s natural muscle activity to shift focus from distance to near, providing clear vision at all distances without the help of glasses or contact lenses.

## **FOR FURTHER INFORMATION, PLEASE CONTACT:**

Dave Burwell  
Director, Investor Relations  
[dave.burwell@ocumetics.com](mailto:dave.burwell@ocumetics.com)  
(403) 410-7907

***Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.***

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION: This news release includes certain “forward-looking statements” under applicable Canadian securities legislation. Forward-looking statements include, but are not limited to, statements with respect to the commencement, timing and scope of the research and development to be conducted by the Company mentioned above. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include but are not limited to: operational matters, historical trends, current conditions and expected future developments, access to financing as well as other considerations that are believed to be appropriate in the circumstances. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.